IGF1 and lung carcinoma: The SOE score for testing for IGF aberrations or IGF levels in lung cancer, however, is currently ‘low’ as much of the data regarding this pathway is pre-clinical while several clinical trials evaluating inhibition of this pathway have been negative or are still ongoing [93], [94].